isobutyrylcarnitine | 25518-50-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: isobutyrylcarnitine
• 英文别名: 3-[(2-Methylpropanoyl)oxy]-4-(trimethylazaniumyl)butanoate；3-(2-methylpropanoyloxy)-4-(trimethylazaniumyl)butanoate
• CAS: 25518-50-7
• 化学式: C₁₁H₂₁NO₄
• 分子量: 231.292
• InChiKey: LRCNOZRCYBNMEP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  66.4
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] L-CARNITINE AND ALKANOYL L-CARNITINE PHYTATES AND PROCESS FOR PREPARING THE SAME<br/>[FR] PHYTATES DE L-CARNITINE ET D'ALCANOYLE L-CARNITINE, ET LEUR PROCÉDÉ DE PRÉPARATION
  申请人：SCIAN LAB LLC

  公开号：WO2010005465A1

  公开（公告）日：2010-01-14

  Salts of L-carnitine and alkanoyl L-carnitines with phytic acid of general formula (I), and the process of preparing the same, wherein the mole ratio between the L-carnitine or its alkanoyl derivatives cation and phytic acid anion be within the range of 1 :1 to 6:1, wherein: n = 1-6; R1 is the phytate anion; R is either hydrogen, a straight alkanoyl group having 2-12 carbon atoms or a branched-chain alkanoyl group having 2-12 carbon atoms.

  L-肉碱盐和烷酰基L-肉碱盐与一般公式(I)的植酸，以及制备这些化合物的过程，其中L-肉碱或其烷酰衍生物阳离子与植酸阴离子之间的摩尔比在1:1至6:1的范围内，其中：n = 1-6；R1为植酸阴离子；R为氢、具有2-12个碳原子的直链烷酰基团或具有2-12个碳原子的支链烷酰基团。
• L-carnitine and alkanoyl L-carnitine phytates and process for preparing the same
  申请人：Chen Jian

  公开号：US20100317890A1

  公开（公告）日：2010-12-16

  Salts of L-carnitine and alkanoyl L-carnitines with phytic acid of general formula (I), and the process of preparing the same, wherein the mole ratio between the L-carnitine or its alkanoyl derivatives cation and phytic acid anion be within the range of 1:1 to 6:1, wherein: n=1-6; R 1 is the phytate anion; R is either hydrogen, a straight alkanoyl group having 2-12 carbon atoms or a branched-chain alkanoyl group having 2-12 carbon atoms.

  L-肉碱盐和辛酰基L-肉碱盐与通式(I)的植酸，以及其制备方法，其中L-肉碱或其辛酰基衍生物阳离子与植酸阴离子之间的摩尔比在1:1至6:1的范围内，其中：n=1-6；R1是植酸阴离子；R是氢，具有2-12个碳原子的直链辛酰基或具有2-12个碳原子的支链辛酰基。
• METHODS FOR USING AND BIOMARKERS FOR AMPK-ACTIVATING COMPOUNDS
  申请人：Hitoshi Yasumichi

  公开号：US20150087673A1

  公开（公告）日：2015-03-26

  Disclosed are methods of using AMPK-activating compounds, for example, in the treatment of cancer and disorders of vascular flow. Also disclosed are biomarkers for AMPK and uses thereof, for example, in the diagnosis and treatment of AMPK-linked disorders. In certain embodiments, the AMPK-activating compounds have the structural formula wherein E, J, T, D 1 , D 2 , D 3 , the ring system denoted by “B”, T, R 3 , R 4 , w and x are as described herein.

  本文公开了使用AMPK激活化合物的方法，例如在癌症和血管流动障碍的治疗中的应用。还公开了AMPK的生物标志物及其用途，例如在AMPK相关疾病的诊断和治疗中的应用。在某些实施例中，AMPK激活化合物具有以下结构式，其中E、J、T、D1、D2、D3、由“B”表示的环系统、T、R3、R4、w和x如本文所述。
• METHODS OF TREATING DISEASES AND DISORDERS RESULTING FROM BETA CORONAVIRUS INFECTION
  申请人：T3D Therapeutics, Inc.

  公开号：US20210369680A1

  公开（公告）日：2021-12-02

  This disclosure describes the use of indane acetic acid derivatives which are PPAR agonists, including PPAR delta, PPAR gamma, and dual PPAR delta and gamma agonists, and which penetrate the blood brain barrier to achieve effective brain to plasma drug levels at non-toxic doses, for the treatment of betacoronavirus diseases, such as COVID-19 and COVID-19 related co-morbid diseases, including Acute Respiratory Distress and CNS disorders, such as delirium and cognitive impairment.

  本公开说明了使用indane乙酸衍生物作为PPAR激动剂，包括PPAR delta，PPAR gamma和双重PPAR delta和gamma激动剂，这些激动剂穿过血脑屏障，在非毒性剂量下实现有效的脑血浆药物水平，用于治疗β冠状病毒疾病，如COVID-19和COVID-19相关的共病疾病，包括急性呼吸窘迫和中枢神经系统疾病，如谵妄和认知障碍。
• Use of L-carnitine derivatives for the manufacture of a medicament for the therapeutical treatment of peripheral neuropathies
  申请人：Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.

  公开号：EP0376899A2

  公开（公告）日：1990-07-04

  The use is disclosed of compounds of general formula wherein: Y is hydrogen, methyl or amino, and R is an unsubstituted or substituted alkyl group selected from methyl, ethyl, 1-methylpropyl, isobutyl, isopropyl, mercaptomethyl and 3-guanidinopropyl and the pharmacologically acceptable salts thereof, for treating degenerative alterations of the nervous system. The compounds can be administered orally or parenterally.

  公开了通式如下的化合物的用途 其中 Y 是氢、甲基或氨基，以及 R 是选自甲基、乙基、1-甲基丙基、异丁基、异丙基、巯基甲基和 3-胍基丙基的未取代或取代的烷基。 及其药理上可接受的盐类，用于治疗神经系统的退行性改变。这些化合物可以口服或肠外给药。